克隆丁补丁治疗图雷特综合征与注意力缺陷/多动障碍
Yanhui Chen1, Zhongling Ke1, Ying Ouyang2
1Fujian Medical University Union Hospital, Fujian, China.
Psychiatry investigation
|May 2, 2024
概括
克洛尼丁贴片有效地减少了图雷特综合征 (TS) 和注意力缺陷/多动症障碍 (ADHD) 的儿童和青少年的滴滴症状. 这种治疗是安全的,只有轻微的不良事件自发消失.
科学领域:
- 神经学 神经学
- 儿科 儿科 儿科
- 药理学 药理学是指药理学的学科.
背景情况:
- 图雷特综合征 (TS) 经常与注意力缺陷/多动障碍 (ADHD) 一起发生.
- 管理伴随性TS和ADHD带来了独特的临床挑战.
- 在TS患者中,经常考虑使用非刺激药物治疗ADHD.
研究的目的:
- 评估克洛尼丁粘合贴在儿童TS患者和并发性ADHD患者的疗效和安全性.
- 为了确定最佳的剂量来控制的症状.
主要方法:
- 一个随机的,安慰剂对照试验,涉及儿童和青少年被诊断患有TS和ADHD.
- 患者被分配给克洛尼丁粘合剂贴片剂量为每周1.0毫克,每周1.5毫克,每周2.0毫克或安慰剂.
- 使用耶鲁大学全球严重程度表,通过斯旺森,诺兰和佩勒姆评分表 (SNAP-IV) 评估了严重程度,通过斯旺森,诺兰和佩勒姆评分表评估了ADHD症状.
主要成果:
- 与安慰剂 (85.7%,81.5%,86.1%与20.7%) 相比,克隆粘合剂贴片在第8周显著改善了滴答障碍 (TD) 的有效率.
- 所有克洛尼丁组的SNAP-IV分数从基线显著改善,尽管在第8周与安慰剂没有统计学上的差异.
- 报告了9种不良反应,所有这些都是轻微的和自我解决的.
结论:
- 克洛尼丁粘合剂贴片是一种安全有效的选择,可以减少TS患者具有并发性多动性多动性多动性多动性多动性多动性多动性多动性综合征的症状.
- 在这种人群中,治疗可能为管理ADHD症状提供潜在的好处.
更多相关视频
相关概念视频
Attention-Deficit/Hyperactivity Disorder
56
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
56
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
Adrenergic Agonists: Therapeutic Uses
770
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
770
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
Cholinergic Antagonists: Pharmacokinetics
436
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
436


